Meryam Sugulle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Meryam Sugulle has a total of 166 co-authors. Here are the top co-authors by number of shared publications:
Anne Cathrine Staff
16 shared publications- Anne Cathrine Staff
Division of Obstetrics and Gynaecology, Oslo University Hospital
10 shared publications Birgitte Mitlid-Mork
Division of Obstetrics and Gynaecology, Oslo University Hospital Ullevål, P.O box 4956 Nydalen, 0424 Oslo, Norway; Faculty of Medicine, University of Oslo, P.O box 1078, Blindern, 0316 Oslo, Norway
5 shared publications- Florian Herse
Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany
5 shared publications - Ralf Dechend
Experimental and Clinical Research Centre (ECRC), Max Delbrück Centre for Molecular Medicine, Berlin, Germany
5 shared publications Sophie Bowe
Division of Obstetrics and Gynaecology, Oslo University Hospital Ullevål, P.O box 4956 Nydalen, 0424 Oslo, Norway; Faculty of Medicine, University of Oslo, P.O box 1078, Blindern, 0316 Oslo, Norway
5 shared publications
Latest Publications
- Open Access
- 19 August 2026
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (11)
Early post-operative complications after fertility-sparing surgery for cervical carcinoma: a retrospective study of a centralized national cohort of 127 consecutive women
- 19 August 2026
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 36 (11)
Open AccessEarly post-operative complications after fertility-sparing surgery for cervical carcinoma: a retrospective study of a centralized national cohort of 127 consecutive women
- Open Access
- 27 June 2026
- Published by Elsevier in Journal of Reproductive Immunology
- Vol. 176, 104928
Circulating neutrophil extracellular traps and deoxyribonuclease in gestational diabetes mellitus
- 27 June 2026
- Published by Elsevier in Journal of Reproductive Immunology
- Vol. 176, 104928
Open AccessCirculating neutrophil extracellular traps and deoxyribonuclease in gestational diabetes mellitus
- 1 June 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (6)
Effects of Antihypertensive Therapy on Pre- and Postnatal Maternal Hemodynamics
BACKGROUND: Hypertensive disorders of pregnancy (HDP) are associated with cardiovascular impairment reflected by abnormal maternal hemodynamics. Current treatment strategies target blood pressure rather than the maternal hemodynamic profile. Therefore, this study evaluated the effects of antihypertensive treatment on cardiovascular parameters in women with HDP, healthy pregnant women, and in a preeclamptic rat model. METHODS: This multicenter, prospective translational case-control study was conducted at the Medical University of Vienna and the Max Delbruck Center for Molecular Medicine, Berlin, between July 2019 and July 2024. Cardiovascular parameters including cardiac output, stroke volume, systemic vascular resistance, and inotropy index were measured pre- and posttreatment with α-methyldopa as well as postnatally using the USCOM 1A Monitor. In the rat model, the effects of α-methyldopa, nifedipine, and labetalol were evaluated. RESULTS: A total of 238 women were included: 132 with HDP (69 gestational hypertension, 63 preeclampsia) and 106 controls. In gestational hypertension, treatment led to increased cardiac output (median, 0.38 L/min [95% CI, 0.06–0.71]; P =0.021) and a decrease in systemic vascular resistance (median, −0.08 log dynes/s per cm −5 [95% CI, −0.14 to −0.03]; P =0.005). In preeclampsia, no significant hemodynamic changes were observed. Systemic vascular resistance remained elevated and stroke volume index reduced in both HDP groups up to 1-year postpartum. Similar patterns were observed in the preeclamptic rat model, with persistently increased vascular resistance and reduced cardiac output and stroke volume. CONCLUSIONS: Antihypertensive therapy does not influence cardiovascular impairment despite lowering blood pressure in preeclampsia. Novel therapeutic approaches are needed to improve maternal cardiovascular health after HDP.
- 1 June 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (6)
Effects of Antihypertensive Therapy on Pre- and Postnatal Maternal Hemodynamics
BACKGROUND: Hypertensive disorders of pregnancy (HDP) are associated with cardiovascular impairment reflected by abnormal maternal hemodynamics. Current treatment strategies target blood pressure rather than the maternal hemodynamic profile. Therefore, this study evaluated the effects of antihypertensive treatment on cardiovascular parameters in women with HDP, healthy pregnant women, and in a preeclamptic rat model. METHODS: This multicenter, prospective translational case-control study was conducted at the Medical University of Vienna and the Max Delbruck Center for Molecular Medicine, Berlin, between July 2019 and July 2024. Cardiovascular parameters including cardiac output, stroke volume, systemic vascular resistance, and inotropy index were measured pre- and posttreatment with α-methyldopa as well as postnatally using the USCOM 1A Monitor. In the rat model, the effects of α-methyldopa, nifedipine, and labetalol were evaluated. RESULTS: A total of 238 women were included: 132 with HDP (69 gestational hypertension, 63 preeclampsia) and 106 controls. In gestational hypertension, treatment led to increased cardiac output (median, 0.38 L/min [95% CI, 0.06–0.71]; P =0.021) and a decrease in systemic vascular resistance (median, −0.08 log dynes/s per cm −5 [95% CI, −0.14 to −0.03]; P =0.005). In preeclampsia, no significant hemodynamic changes were observed. Systemic vascular resistance remained elevated and stroke volume index reduced in both HDP groups up to 1-year postpartum. Similar patterns were observed in the preeclamptic rat model, with persistently increased vascular resistance and reduced cardiac output and stroke volume. CONCLUSIONS: Antihypertensive therapy does not influence cardiovascular impairment despite lowering blood pressure in preeclampsia. Novel therapeutic approaches are needed to improve maternal cardiovascular health after HDP.
- Open Access
- 29 May 2026
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 105 (8) , 1414-1416
Ancestry‐based antihypertensive therapy: Beware of pitfalls
- 29 May 2026
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 105 (8) , 1414-1416
Open AccessAncestry‐based antihypertensive therapy: Beware of pitfalls
- 11 May 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (6) , 1977-1978
A new treatment for preterm pre-eclampsia could benefit mother and child
- 11 May 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (6) , 1977-1978
A new treatment for preterm pre-eclampsia could benefit mother and child
- Open Access
Placenta tissue-based and circulating markers of cellular senescence in gestational diabetes mellitus
- Top Cited PapersOpen Access
- 27 January 2026
- Published by SAGE Publications in Health Informatics Journal
- Vol. 32 (1)
Hypertensive disorders of pregnancy: The use of eHealth technologies in postpartum follow-up strategies to reduce cardiovascular risk – A scoping review
Objective: Women with prior hypertensive disorders of pregnancy (HDP) have increased risk of developing future cardiovascular disease. The objective of this scoping review was to map the literature regarding the use of eHealth measures in cardiovascular follow-up after HDP and identify research gaps. Methods: A systematic search was conducted in four databases. Primary research articles and guidelines were included. Abstract screening, full-text assessment and data extraction was performed to summarize the findings. Results: The search identified 4830 articles and 12 guidelines. Eleven publications and one guideline were included in the analyses. Various eHealth interventions were assessed, such as remote blood pressure monitoring, physical activity and weight management, with follow-up time from 6 weeks to 4 years. eHealth interventions targeting blood pressure and physical activity showed statistically significant positive effects. Conclusion: The scoping review identified eHealth interventions for cardiovascular follow-up after HDP that may empower women to optimize their cardiovascular health.
- 27 January 2026
- Published by SAGE Publications in Health Informatics Journal
- Vol. 32 (1)
Top Cited PapersOpen AccessHypertensive disorders of pregnancy: The use of eHealth technologies in postpartum follow-up strategies to reduce cardiovascular risk – A scoping review
Objective: Women with prior hypertensive disorders of pregnancy (HDP) have increased risk of developing future cardiovascular disease. The objective of this scoping review was to map the literature regarding the use of eHealth measures in cardiovascular follow-up after HDP and identify research gaps. Methods: A systematic search was conducted in four databases. Primary research articles and guidelines were included. Abstract screening, full-text assessment and data extraction was performed to summarize the findings. Results: The search identified 4830 articles and 12 guidelines. Eleven publications and one guideline were included in the analyses. Various eHealth interventions were assessed, such as remote blood pressure monitoring, physical activity and weight management, with follow-up time from 6 weeks to 4 years. eHealth interventions targeting blood pressure and physical activity showed statistically significant positive effects. Conclusion: The scoping review identified eHealth interventions for cardiovascular follow-up after HDP that may empower women to optimize their cardiovascular health.
- Top Cited PapersOpen Access
- 1 May 2025
- Published by Wolters Kluwer Health in Hypertension
- Vol. 82 (5) , 787-799
Senescent Syncytiotrophoblast Secretion During Early Onset Preeclampsia
BACKGROUND: Preeclampsia is a severe hypertensive disorder in pregnancy that causes preterm delivery, maternal and fetal morbidity, mortality, and life-long sequelae. Understanding the pathogenesis of preeclampsia is a critical first step toward protecting mother and child from this syndrome and increased risk of cardiovascular disease later in life. However, effective early predictive tests and therapies for preeclampsia are scarce. METHODS: To identify novel markers and signaling pathways for early onset preeclampsia, we profiled human maternal-fetal interface units (fetal villi and maternal decidua) from early onset preeclampsia and healthy controls using single-nucleus RNA sequencing combined with spatial transcriptomics. The placental syncytiotrophoblast is in direct contact with maternal blood and forms the barrier between fetal and maternal circulation. RESULTS: We identified different transcriptomic states of the endocrine syncytiotrophoblast nuclei with patterns of dysregulation associated with a senescence-associated secretory phenotype and a spatial dysregulation of senescence in the placental trophoblast layer. Elevated senescence markers were validated in placental tissues of clinical multicenter cohorts. Importantly, several secreted senescence-associated secretory phenotype factors were elevated in maternal blood already in the first trimester. We verified the secreted senescence markers, PAI-1 (plasminogen activator inhibitor 1) and activin A, as identified in our single-nucleus RNA sequencing model as predictive markers before clinical preeclampsia diagnosis. CONCLUSIONS: This indicates that increased syncytiotrophoblast senescence appears weeks before clinical manifestation of early onset preeclampsia, suggesting that the dysregulated preeclamptic placenta starts with higher cell maturation resulting in premature and increased senescence-associated secretory phenotype release. These senescence-associated secretory phenotype markers may serve as an additional early diagnostic tool for this syndrome.
- 1 May 2025
- Published by Wolters Kluwer Health in Hypertension
- Vol. 82 (5) , 787-799
Top Cited PapersOpen AccessSenescent Syncytiotrophoblast Secretion During Early Onset Preeclampsia
BACKGROUND: Preeclampsia is a severe hypertensive disorder in pregnancy that causes preterm delivery, maternal and fetal morbidity, mortality, and life-long sequelae. Understanding the pathogenesis of preeclampsia is a critical first step toward protecting mother and child from this syndrome and increased risk of cardiovascular disease later in life. However, effective early predictive tests and therapies for preeclampsia are scarce. METHODS: To identify novel markers and signaling pathways for early onset preeclampsia, we profiled human maternal-fetal interface units (fetal villi and maternal decidua) from early onset preeclampsia and healthy controls using single-nucleus RNA sequencing combined with spatial transcriptomics. The placental syncytiotrophoblast is in direct contact with maternal blood and forms the barrier between fetal and maternal circulation. RESULTS: We identified different transcriptomic states of the endocrine syncytiotrophoblast nuclei with patterns of dysregulation associated with a senescence-associated secretory phenotype and a spatial dysregulation of senescence in the placental trophoblast layer. Elevated senescence markers were validated in placental tissues of clinical multicenter cohorts. Importantly, several secreted senescence-associated secretory phenotype factors were elevated in maternal blood already in the first trimester. We verified the secreted senescence markers, PAI-1 (plasminogen activator inhibitor 1) and activin A, as identified in our single-nucleus RNA sequencing model as predictive markers before clinical preeclampsia diagnosis. CONCLUSIONS: This indicates that increased syncytiotrophoblast senescence appears weeks before clinical manifestation of early onset preeclampsia, suggesting that the dysregulated preeclamptic placenta starts with higher cell maturation resulting in premature and increased senescence-associated secretory phenotype release. These senescence-associated secretory phenotype markers may serve as an additional early diagnostic tool for this syndrome.
- Open Access
- 29 March 2025
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 170 (3) , 1309-1316
Effects of fetal presentation on mode of delivery in 26 143 twin pregnancies: A nationwide, population‐based observational study of 31‐year real‐world data
Objective: To describe the rate of combinations of fetal lies and presentations in twin pregnancies at delivery and to assess the effects of fetal lies and presentations on mode of delivery as well as fetal and maternal birth outcomes.Methods: This population‐based cohort study used real‐world data from the Medical Birth Registry of Norway and included all twin births (n = 26 143) in Norway during 1988–2018. Logistic Regression Analysis was Applied. Main outcome measures were planned and actual modes of delivery categorized into vaginal deliveries and cesarean sections. Secondary outcomes were postpartum hemorrhage and intrapartum stillbirth.Results: Most twin births were planned as vaginal deliveries (83.4%, 21 811/26 143), of which (65.9%, 14 371/21 811) were successful. Vaginal delivery was more often successful in parous than in nulliparous women, or if the first or both twins were in cephalic presentation compared with non‐cephalic presentation of the first or both twins. Planned cesarean section was more likely to be chosen if the first or both twins were in non‐cephalic presentation than if they were in cephalic presentation. Maternal parity, demographic and obstetric risk factors had little or no effect on the association between twin presentations and planned or actual delivery mode.Conclusions: More than half of women with a twin pregnancy had a successful vaginal delivery. Keeping the option of the vaginal route as the primary mode of delivery in a twin pregnancy maintains the right of the woman to have a vaginal delivery and avoid a uterine scar.
- 29 March 2025
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 170 (3) , 1309-1316
Open AccessEffects of fetal presentation on mode of delivery in 26 143 twin pregnancies: A nationwide, population‐based observational study of 31‐year real‐world data
Objective: To describe the rate of combinations of fetal lies and presentations in twin pregnancies at delivery and to assess the effects of fetal lies and presentations on mode of delivery as well as fetal and maternal birth outcomes.Methods: This population‐based cohort study used real‐world data from the Medical Birth Registry of Norway and included all twin births (n = 26 143) in Norway during 1988–2018. Logistic Regression Analysis was Applied. Main outcome measures were planned and actual modes of delivery categorized into vaginal deliveries and cesarean sections. Secondary outcomes were postpartum hemorrhage and intrapartum stillbirth.Results: Most twin births were planned as vaginal deliveries (83.4%, 21 811/26 143), of which (65.9%, 14 371/21 811) were successful. Vaginal delivery was more often successful in parous than in nulliparous women, or if the first or both twins were in cephalic presentation compared with non‐cephalic presentation of the first or both twins. Planned cesarean section was more likely to be chosen if the first or both twins were in non‐cephalic presentation than if they were in cephalic presentation. Maternal parity, demographic and obstetric risk factors had little or no effect on the association between twin presentations and planned or actual delivery mode.Conclusions: More than half of women with a twin pregnancy had a successful vaginal delivery. Keeping the option of the vaginal route as the primary mode of delivery in a twin pregnancy maintains the right of the woman to have a vaginal delivery and avoid a uterine scar.